Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future

References

• Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet 2009;373:1550–1561.
   PubMed Web of Science ®Google Scholar
• Woolfrey A, Lee SJ, Gooley TA, et al. HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category. Biol Blood Marrow Transplant 2010;16:1382–1387.
   PubMed Web of Science ®Google Scholar
• Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000;95:3702–3709.
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756–762.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991;77:1423–1428.
   PubMed Web of Science ®Google Scholar
• Ruutu T, van Biezen A, Hertenstein B, et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012;47:1459–1464.
   PubMed Web of Science ®Google Scholar
• Mathe G, Amiel JL, Schwarzenberg L, et al. Haematopoietic chimera in man after allogenic (homologous) bone-marrow transplantation. (Control of the secondary syndrome. Specific tolerance due to the chimerism). Br Med J 1963;2:1633–1635.
   PubMedGoogle Scholar
• Epstein RB, Storb R, Ragde H, et al. Cytotoxic typing antisera for marrow grafting in littermate dogs. Transplantation 1968;6:45–58.
   PubMed Web of Science ®Google Scholar
• Storb R, Epstein RB, Bryant J, et al. Marrow grafts by combined marrow and leukocyte infusions in unrelated dogs selected by histocompatibility typing. Transplantation 1968;6:587–593.
   PubMed Web of Science ®Google Scholar
• Storb R, Rudolph RH, Thomas ED. Marrow grafts between canine siblings matched by serotyping and mixed leukocyte culture. J Clin Invest 1971;50:1272–1275.
   PubMed Web of Science ®Google Scholar
• Storb R, Epstein RB, Graham TC, et al. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970;9:240–246.
   PubMed Web of Science ®Google Scholar
• Storb R, Graham TC, Shiurba R, et al. Treatment of canine graft-versus-host disease with methotrexate and cyclo-phosphamide following bone marrow transplantation from histoincompatible donors. Transplantation 1970;10:165–172.
   PubMed Web of Science ®Google Scholar
• Mathe G, Amiel JL, Schwarzenberg L, et al. Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J 1970;2:131–136.
   PubMed Web of Science ®Google Scholar
• Buckner CD, Epstein RB, Rudolph RH, et al. Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia. Blood 1970;35:741–750.
   PubMed Web of Science ®Google Scholar
• Thomas ED, Buckner CD, Rudolph RH, et al. Allogeneic marrow grafting for hematologic malignancy using HL-A matched donor-recipient sibling pairs. Blood 1971;38:267–287.
   PubMed Web of Science ®Google Scholar
• den Haan JM, Sherman NE, Blokland E, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995;268:1476–1480.
   PubMed Web of Science ®Google Scholar
• Weisdorf D, Hakke R, Blazar B, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991;51:1197–1203.
   PubMed Web of Science ®Google Scholar
• Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft- versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001;19:3685–3691.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999;94:1465–1470.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011;117:3214–3219.
   PubMed Web of Science ®Google Scholar
• van der Velden WJ, Netea MG, de Haan AF, et al. The role of the mycobiome in human acute graft-versus-host disease. Biol Blood Marrow Transplant 2012 Nov 15. [Epub ahead of print]
   Google Scholar
• Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012;54:1053–1063.
   PubMed Web of Science ®Google Scholar
• Cantoni N, Hirsch HH, Khanna N, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant 2010;16: 1309–1314.
   PubMed Web of Science ®Google Scholar
• Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood 2012 Nov 19. [Epub ahead of print]
   Google Scholar
• Uphoff DE. Alteration of homograft reaction by A-methopterin in lethally irradiated mice treated with homologous marrow. Proc Soc Exp Biol Med 1958;99:651–653.
   PubMed Web of Science ®Google Scholar
• Lochte HL Jr, Levy AS, Guenther DM, et al. Prevention of delayed foreign marrow reaction in lethally irradiated mice by early administration of methotrexate. Nature 1962;196:1110–1111.
   PubMed Web of Science ®Google Scholar
• Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975;292:832–843.
   PubMed Web of Science ®Google Scholar
• Storb R, Antin JH, Cutler C. Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? Biol Blood Marrow Transplant 2010;16:S18–S27.
   Google Scholar
• Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92:2303–2314.
   PubMed Web of Science ®Google Scholar
• Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000;96:2062–2068.
   PubMed Web of Science ®Google Scholar
• Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80:1838–1845.
   PubMed Web of Science ®Google Scholar
• von Bueltzingsloewen A, Belanger R, Perreault C, et al. Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies. Blood 1993;81:849–855.
   PubMed Web of Science ®Google Scholar
• Murphy NM, Diviney M, Szer J, et al. The effect of folinic acid on methylenetetrahydrofolate reductase polymorphisms in methotrexate-treated allogeneic hematopoietic stem cell transplants. Biol Blood Marrow Transplant 2012;18:722–730.
   PubMed Web of Science ®Google Scholar
• Gori E, Arpinati M, Bonifazi F, et al. Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. Bone Marrow Transplant 2007;39:347–352.
   PubMed Web of Science ®Google Scholar
• Powles RL, Barrett AJ, Clink H, et al. Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet 1978;2:1327–1331.
   PubMed Web of Science ®Google Scholar
• Hows JM, Chipping PM, Fairhead S, et al. Nephrotoxicity in bone marrow transplant recipients treated with cyclosporin A. Br J Haematol 1983;54:69–78.
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Storb R, Thomas ED, et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985;65:1325–1334.
   PubMed Web of Science ®Google Scholar
• Storb R, Deeg HJ, Thomas ED, et al. Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood 1985;66:698–702.
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Kendra JR, Lucas CF, et al. Cyclosporin A as prophylaxis against graft-versus-host disease in 36 patients. Br Med J (Clin Res Ed) 1982;285:162–166.
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Storb R, Weiden PL, et al. Cyclosporin A and methotrexate in canine marrow transplantation: engraftment, graft-versus-host disease, and induction of intolerance. Transplantation 1982;34:30–35.
   PubMed Web of Science ®Google Scholar
• Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986;314:729–735.
   PubMed Web of Science ®Google Scholar
• Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986;68:119–125.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Leisenring W, Deeg HJ, et al. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Biol Blood Marrow Transplant 2005;11:814–815.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Leisenring W, Deeg HJ, et al. Re: Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:567–568.
   PubMed Web of Science ®Google Scholar
• Ram R, Gafter-Gvili A, Yeshurun M, et al. Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant 2009;43:643–653.
   PubMed Web of Science ®Google Scholar
• Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem 2001;34:9–16.
   PubMed Web of Science ®Google Scholar
• Craddock C, Nagra S, Peniket A, et al. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2010;95:989–995.
   PubMed Web of Science ®Google Scholar
• Ram R, Storer B, Mielcarek M, et al. Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:414–422.
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Flowers ME, Lee SJ, et al. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood 2011;118: 456–463.
   PubMed Web of Science ®Google Scholar
• Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987;40:1249–1255.
   PubMed Web of Science ®Google Scholar
• Bishop DK, Li W. Cyclosporin A and FK506 mediate differential effects on T cell activation in vivo. J Immunol 1992;148:1049–1054.
   PubMed Web of Science ®Google Scholar
• Shaw KT, Ho AM, Raghavan A, et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA 1995; 92:11205–11209.
   PubMed Web of Science ®Google Scholar
• Peters DH, Fitton A, Plosker GL, et al. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46:746–794.
   PubMed Web of Science ®Google Scholar
• Blazar BR, Taylor PA, Fitzsimmons WE, et al. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation. J Immunol 1994; 153:1836–1846.
   PubMed Web of Science ®Google Scholar
• Storb R, Raff RF, Appelbaum FR, et al. FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. Transplantation 1993;56:800–807.
   PubMed Web of Science ®Google Scholar
• Nash RA, Etzioni R, Storb R, et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995;85:3746–3753.
   PubMed Web of Science ®Google Scholar
• Uberti JP, Silver SM, Adams PT, et al. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1997;19:1233–1238.
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Ohashi Y, Okamoto S, et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001;28:181–185.
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Flowers ME, Appelbaum FR, et al. A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. Biol Blood Marrow Transplant 2012;17:1088–1092.
   Web of Science ®Google Scholar
• Cohen JJ, Fschbach M, Claman HN. Hydrocortisone resistance of graft vs host activity in mouse thymus, spleen and bone marrow. J Immunol 1970;105:1146–1150.
   PubMed Web of Science ®Google Scholar
• Holler E, Kolb HJ, Wilmanns W. Treatment of GVHD– TNF-antibodies and related antagonists. Bone Marrow Transplant 1993;12:S29–S31.
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Lin D, Leisenring W, et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 1997;89:3880–3887.
   PubMed Web of Science ®Google Scholar
• Storb R, Pepe M, Anasetti C, et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990;76:1037–1045.
   PubMed Web of Science ®Google Scholar
• Quellmann S, Schwarzer G, Hubel K, et al. Corticosteroids in the prevention of graft-vs-host disease after allogeneic myeloablative stem cell transplantation: a systematic review and meta-analysis. Leukemia 2008;22:1801–1803.
   PubMed Web of Science ®Google Scholar
• Sayer HG, Longton G, Bowden R, et al. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 1994;84:1328–1332.
   PubMed Web of Science ®Google Scholar
• Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997;63:39–47.
   PubMed Web of Science ®Google Scholar
• Yu C, Seidel K, Nash RA, et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 1998;91:2581–2587.
   PubMed Web of Science ®Google Scholar
• McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390–3400.
   PubMed Web of Science ®Google Scholar
• Giaccone L, McCune JS, Maris MB, et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood 2005;106:4381–4388.
   PubMed Web of Science ®Google Scholar
• Perkins J, Field T, Kim J, et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2010;16:937–947.
   PubMed Web of Science ®Google Scholar
• Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004;34:621–625.
   PubMed Web of Science ®Google Scholar
• Kiehl MG, Schafer-Eckart K, Kroger M, et al. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients. Transplant Proc 2002;34:2922–2924.
   PubMed Web of Science ®Google Scholar
• Dean R, Rybicki L, Sobecks R, et al. Comparison of cyclosporine and methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Blood 2008;112: Abstract 2240.
   Web of Science ®Google Scholar
• Srinivasan R, Geller N, Chakrabarti S, et al. Evaluation of three different cyclosporine-based graft versus host disease (GVHD) prophylaxis regimens following nonmyeloablative hematopoietic stem cell transplantation. Blood 2004;104: Abstract 1236.
   PubMed Web of Science ®Google Scholar
• Storb R, Gluckman E, Thomas ED, et al. Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood 1974;44:56–75.
   PubMedGoogle Scholar
• Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007;21:1387–1394.
   PubMed Web of Science ®Google Scholar
• Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009;10:855–864.
   PubMed Web of Science ®Google Scholar
• Socie G, Schmoor C, Bethge WA, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011;117:6375–6382.
   PubMed Web of Science ®Google Scholar
• Kumar A, Mhaskar AR, Reljic T, et al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia 2012;26:582–588.
   PubMed Web of Science ®Google Scholar
• Atta EH, de Sousa AM, Schirmer MR, et al. Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia. Biol Blood Marrow Transplant 2012;18:1876–1882.
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011;365:430–438.
   PubMed Web of Science ®Google Scholar
• Atta EH, Dias DS, Marra VL, et al. Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol 2010;89:851–859.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Lerademacher J, Ho V, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011;117:6963–6970.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001;98:2942–2947.
   PubMed Web of Science ®Google Scholar
• Johnson RW. Sirolimus (Rapamune) in renal transplantation. Curr Opin Nephrol Hypertens 2002;11:603–607.
   PubMed Web of Science ®Google Scholar
• Abouelnasr A, Cohen S, Kiss T, et al. Defining the role of sirolimus in the management of graft-versus-host disease: from prophylaxis to treatment. Biol Blood Marrow Transplant 2012 Jul 5. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335–340.
   PubMed Web of Science ®Google Scholar
• Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008;112:4425–4431.
   PubMed Web of Science ®Google Scholar
• Rosenbeck LL, Kiel PJ, Kalsekar I, et al. Prophylaxis with sirolimus and tacrolimus +/- antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011;17:916–922.
   PubMed Web of Science ®Google Scholar
• Pidala J, Kim J, Jim H, et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 2012;97:1882–1889.
   PubMed Web of Science ®Google Scholar
• Armand P, Gannamaneni S, Kim HT, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008;26:5767–5774.
   PubMed Web of Science ®Google Scholar
• Furlong T, Kiem HP, Appelbaum FR, et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant 2008;14:531–537.
   PubMed Web of Science ®Google Scholar
• Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994;13:597–611.
   PubMed Web of Science ®Google Scholar
• Hamblin M, Marsh JC, Lawler M, et al. Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors. Bone Marrow Transplant 1996;17:819–824.
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002;100:3121–3127.
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99:1071–1078.
   PubMed Web of Science ®Google Scholar
• Marsh JC, Gupta V, Lim Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011;118:2351–2357.
   PubMed Web of Science ®Google Scholar
• Mead AJ, Thomson KJ, Morris EC, et al. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood 2011;115:5147–5153.
   Web of Science ®Google Scholar
• Luznik L, Bolanos-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010;115:3224–3230.
   PubMed Web of Science ®Google Scholar
• Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplant and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2012 Aug 29. [Epub ahead of print]
   Web of Science ®Google Scholar
• Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14:641–650.
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, et al. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009;114:4919–4927.
   PubMed Web of Science ®Google Scholar
• Crocchiolo R, Castagna L, El-Cheikh J, et al. Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients. Exp Hematol 2011;39:892–896.
   PubMed Web of Science ®Google Scholar
• Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006;18:349–356.
   PubMed Web of Science ®Google Scholar
• Kappel LW, Goldberg GL, King CG, et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 2009;113:945–952.
   PubMed Web of Science ®Google Scholar
• Iclozan C, Yu Y, Liu C, et al. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Transplant 2010;16:170–178.
   PubMed Web of Science ®Google Scholar
• Teshima T, Maeda Y, Ozaki K. Regulatory T cells and IL-17-producing cells in graft-versus-host disease. Immunotherapy 2011;3:833–852.
   PubMed Web of Science ®Google Scholar
• Beres AJ, Haribhai D, Chadwick AC, et al. CD8 + Foxp3 + regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. J Immunol 2012;189:464–474.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Baker J, Leveson-Gower DB, et al. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4 + CD25+ Foxp3 + regulatory T cells. Blood 2011;118:2342–2350.
   PubMed Web of Science ®Google Scholar
• Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2011;116:129–139.
   Web of Science ®Google Scholar
• Goodyear OC, Dennis M, Jilani NY, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012;119: 3361–3369.
   PubMed Web of Science ®Google Scholar
• Briones J, Novelli S, Sierra J. T-cell costimulatory molecules in acute-graft-versus host disease: therapeutic implications. Bone Marrow Res 2011;2011:976793.
   PubMedGoogle Scholar
• Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001;1:220–228.
   PubMed Web of Science ®Google Scholar
• Saito K, Sakurai J, Ohata J, et al. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. J Immunol 1998;160:4225–4231.
   PubMed Web of Science ®Google Scholar
• Wallace PM, Johnson JS, MacMaster JF, et al. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 1994;58:602–610.
   PubMed Web of Science ®Google Scholar
• Speiser DE, Bachmann MF, Shahinian A, et al. Acute graft-versus-host disease without costimulation via CD28. Transplantation 1997;63:1042–1044.
   PubMed Web of Science ®Google Scholar
• Yu XZ, Martin PJ, Anasetti C. Role of CD28 in acute graft-versus-host disease. Blood 1998;92:2963–2970.
   PubMed Web of Science ®Google Scholar
• Yu C, Linsley P, Seidel K, et al. Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model. Transplantation 2000;69:450–454.
   PubMed Web of Science ®Google Scholar
• Poirier N, Mary C, Dilek N, et al. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab’ antibody. Am J Transplant 2012;12:2630–2640.
   PubMed Web of Science ®Google Scholar
• Betts BC, Abdel-Wahab O, Curran SA, et al. Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. Blood 2011;118:5330–5339.
   PubMed Web of Science ®Google Scholar
• Koreth J, Stevenson KE, Kim HT, et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009;114: 3956–3959.
   PubMed Web of Science ®Google Scholar
• Sun K, Wilkins DE, Anver MR, et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 2005; 106:3293–3299.
   PubMed Web of Science ®Google Scholar
• Reddy P, Sun Y, Toubai T, et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008;118:2562–2573.
   PubMed Web of Science ®Google Scholar
• Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007;13:1299–1307.
   PubMed Web of Science ®Google Scholar
• Choi S, Reddy P. HDAC inhibition and graft versus host disease. Mol Med 2011;17:404–416.
   PubMed Web of Science ®Google Scholar
• Fang J, Hu C, Hong M, et al. Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2012;18:754–762.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Hofmeister CC, Jansak B, et al. Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. Biol Blood Marrow Transplant 2008;14:783–789.
   PubMed Web of Science ®Google Scholar
• Choi SW, Stiff P, Cooke K, et al. TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes. Biol Blood Marrow Transplant 2012;18:1525–1532.
   PubMed Web of Science ®Google Scholar